FLAURA2 Final OS (WCLC25) 1L EGFRm NSCLC: Osi+Chemo vs Osi alone mOS 47.5 vs 37.6 mo HR 0.77 (95% CI 0.61–0.96; p=0.02) 3-yr OS: 63% vs 51% Benefit consistent across subgroups AEs: manageable, Osi discontinuation 12% vs 7% 📌 Adds ~10 mo survival, but at cost of prolonged

✅ FLAURA-2 meets the expectations. Final OS analyis: 10 months gain over osi alone, HR 0.77, total of 47.5 months Osi + Chemo. New landmark for EGFRmut lung cancer. 👌 Chemo rechallenge will become an option. Congrats d.planchard for a fantastic presentation. #WCLC25 #LCSM

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

What an achievement for ROS1 pts. Alexander Drilon MD reported the updated result of the ARROS1 trial. Impressive RR (89#) and duration of response with favorable safety profile in naive pts treated with Zidesamtinib. #WCLC2025

EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

The new FLAURA2 OS data presented at #WCLC25 is exciting - nearly four years of median OS with osimertinib + chemotherapy is remarkable progress for our community! Alongside the MARIPOSA data, it's essential to remember -- this isn't about competition. There is no

#WCLC25 | TROPION-Lung01 (post hoc, CNS analysis) 🧠 Dato-DXd showed intracranial activity in NSCLC with brain mets 📊 CNS cORR 38% (measurable disease) ✅ All responders = nonsq NSCLC (incl. EGFRm) ⚖️ No CNS responses with docetaxel 👉 Supports role of TROP2-ADC even in pts

Happy to share the results of our psychosocial long term burden evaluation of French patients living with ALK disease. 82% of psychological difficulties and many others. Lower perception by oncologists. alk ros1 france cancer poumon #rcorre #bmennecier

🔥🚨OncoAlert HOT OFF THE PRESS. Just published The Lancet Oncology In conjunction with presentation IASLC #WCLC25 Impressive Results of: ⭐️#DeLLphi303: Phase 1b trial of: #Tarlatamab + anti-PD-L1 as #maintenance Tx after 1st line Chemo/IO in ES #SmallCell #LungCancer

🫁 ERS 2025 | Amsterdam Session commune SPLF/ERS en Français 🇫🇷 🗓️ 27 septembre 2025 🕛 11h15-12h45 👉 Programme : k4.ersnet.org/prod/v2/Front/… #ERS2025 #respiratoire #pneumologie #cancer #poumons #congres #tuberculose #bpco

➡️ #UrbanTrail Fondation du Souffle : Suite des témoignages des patients, proches aidants et soignants réunis au sein d'une même équipe dimanche🏃‍♂️🏃‍♀️ alk ros1 france cancer poumon Mon Réseau Cancer du Poumon #CancerDuPoumon #Recherche

Un grand bravo aux 47 patients/aidants/soignants de la team alk ros1 france cancer poumon Mon Réseau Cancer du Poumon IFCT lung qui ont gravi les 1200 marches de la Butte Montmartre dimanche dernier ! Rendez-vous l'année prochaine toujours plus nombreux ! #recherche #cancer #poumon Fondation du Souffle

📢 Final #CHRYSALIS report: Krebs et al. show amivantamab demonstrates antitumor activity in METex14 advanced NSCLC, including patients progressing on prior MET therapies. Full findings: bit.ly/3K8o9nZ #LCSM #Oncology #LungCancer Division of Cancer Sciences Manchester Cancer Research Centre Matthew Krebs

Un grand merci à nos orateurs et aux nombreux participants pour cette session commune SPLF-ERS. L’ERS s’ouvre avec une session d’exception ! 🌍✨

🚨 Excited to share our 2 new studies published today in The Lancet Oncology — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. OncoAlert IASLC #LCSM. /W✨Alessandro Di Federico✨

Congrats to Michael Duruisseaux for his presentation of the IFCT-2003 ALBATROS results (phase 2, #lorlatinib after ROS1-TKI failure, 54 pts, 23 centers): BICR-confirmed ORR at 8 wk 34.0%, CNS ORR 92%, median DoR 20.4 mo, median PFS 7.4 mo and median OS 42.3 mo. denis Moro-Sibilot #ESMO25

ALEX final OS: - crizo arm dragged down by <50% getting next-gen ALK. Lack of crossover really hurts. - 5-yr OS with alectinib ≈ 5-yr PFS with lorlatinib (CROWN), but only 18% got lorla post alect — we still don’t know the optimal sequence. #ESMO25

Binding PD-1 and VEGF does not mean only target neoangiogenis but also immune exhaustion. VEGF, like PD-1, is responsabile of T-cell exhaustion and double blockade means to deeply reinvigorates T-cells. In this setting, PD-L1 expression may loose its predictive power. #ESMO25

📍Live from ESMO: IFCT abstracts at a glance 🔬#ESMO25 #NSCLC

mRNA vaccines as unplanned immunotherapy primers ⚡ SARS-CoV-2 mRNA vaccination triggers a type I IFN surge, activates APCs, and primes CD8⁺ T cells for tumor antigen recognition. 🧩 IFN-driven PD-L1 upregulation 🧭 Enhanced T-cell infiltration into “cold” tumors 🌐